The European Union finally has a second vaccine.
Two weeks after giving the green light to Pfizer / BioNTech, the European Medicines Agency (EMA) approved the vaccine from the American biotech Moderna, already licensed in the United States, Israel and Canada.
“
This vaccine provides us with another tool to overcome the current emergency
,” says EMA Director General Emer Cooke.
"A second vaccine available is a second source of supply, and therefore a rise in vaccination,"
tweeted Agnès Pannier-Runacher, Minister of Industry, who was at the heart of discussions with laboratories .
Read also:
Covid: is France at risk of a vaccine shortage?
The authorization given to Moderna's vaccine, which has an efficacy rate of 94.1% against Covid-19, should help ease the pressure on Member States, strongly criticized for the slowness of vaccination.
Especially since this vaccine has the advantage of having to be stored at - 20 ° C, the temperature of a conventional freezer, and not at - 70
This article is for subscribers only.
You have 78% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT
Already subscribed?
Log in